INSPECS Group plc (LON:SPEC – Get Free Report)’s share price shot up 4.2% during trading on Wednesday . The company traded as high as GBX 100 and last traded at GBX 100. 1 shares changed hands during mid-day trading, a decline of 100% from the average daily volume of 409,028 shares. The stock had previously closed at GBX 96.
INSPECS Group Price Performance
The firm has a market cap of £104.81 million, a PE ratio of -10.21 and a beta of 1.60. The company has a debt-to-equity ratio of 74.99, a current ratio of 1.32 and a quick ratio of 0.89. The business has a fifty day moving average price of GBX 95.48 and a two-hundred day moving average price of GBX 88.62.
INSPECS Group (LON:SPEC – Get Free Report) last announced its quarterly earnings data on Thursday, September 10th. The company reported GBX (0.13) EPS for the quarter. INSPECS Group had a negative return on equity of 6.07% and a negative net margin of 2.67%. On average, analysts anticipate that INSPECS Group plc will post 5.5500982 EPS for the current fiscal year.
INSPECS Group Company Profile
Inspecs is a designer, manufacturer and distributor of eyewear frames. The Group produces a broad range of frames, covering optical, sunglasses and safety, which are either “Branded” (either under licence or under the Group’s own proprietary brands), or “OEM” (including private label on behalf of retail customers and un-branded). As one of only a few companies that can offer this one-stop-shop solution to global retail chains, Inspecs is well positioned to continue to take market share in the globally expanding eyewear market.
Inspecs customers include global optical and non-optical retailers, global distributors and independent opticians, with its distribution network covering over 80 countries and reaching approximately 30,000 points of sale.
Recommended Stories
- Five stocks we like better than INSPECS Group
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for INSPECS Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INSPECS Group and related companies with MarketBeat.com's FREE daily email newsletter.
